Amit Khasgiwala
Mr. Khasgiwala has over seven years of experience across investment banking, equity research, and engineering in the medical technology, life science, and healthcare services sectors. Prior to joining Innovatus in September 2017, Mr. Khasgiwala worked Bank of America Merrill Lynch in the healthcare investment banking group. In this position he developed strategic materials and analyses on performing IPOs, equity transactions, strategic acquisitions and sales, and leverage buyouts totaling over $100 billion in transactions. Mr. Khasgiwala advised on various IPOs and acquisitions; including Integra Lifesciences’ $1 billion acquisition of Johnson & Johnson’s neurosurgical products, which resulted in expanded geographic reach and an increase in sales from $1 billion to $2 billion. Additionally, he built life science, medical technology, and healthcare REIT LBO models and sensitivities for prospective clients.
Before working at Bank of America Merrill Lynch, Mr. Khasgiwala was a summer intern at UBS in the equity research group, where he researched and analyzed pharmaceutical companies using financial statements, patent submissions, and clinical prescription trackers; modeled companies using DCF & Relative Valuation methodologies, and presented rating changes on biopharma companies to research management. From 2011 to 2014, Mr. Khasgiwala was a Senior Automation Engineer at NNE Pharmaplan, a company that focuses on end-to-end engineering services tailored specifically towards the pharmaceutical industry. At NNE, he consulted with biotech clients on manufacturing processes funded by a combined total of $100 million capital investments and managed automated production of Phase IV drugs in FDA regulated facilities. From 2008 through 2011, he was an Applications Services Associate at Merck & Co., Inc. where he designed automated manufacturing processes for high-valued vaccines using highly quantitative skills and knowledge of bio-sterile vaccine production.
Mr. Khasgiwala received an Bachelor of Engineering from the University of Pennsylvania with a concentration in Bioengineering and a minor in Economics, and a MBA from The Stern School of Business at New York University, with an emphasis on corporate finance, strategy and financial instruments and markets.